Company Filing History:
Years Active: 2025
Title: Innovations of Liang Fang in JAK Inhibitor Development
Introduction
Liang Fang is a notable inventor based in Guangdong, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of JAK inhibitors. With a total of 2 patents, his work focuses on innovative solutions for treating diseases related to JAK1 and TYK2.
Latest Patents
Liang Fang's latest patents include the "Crystalline form of JAK inhibitor and application thereof." This invention discloses crystal forms of a JAK inhibitor and their application in drug preparation for treating JAK1 or/and TYK2 related diseases. Another significant patent is the "Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases." This patent details the use of a specific JAK inhibitor compound, [1,2,4]-triazolo-[1,5-a]pyridine, in the preparation of drugs aimed at treating autoimmune, inflammatory, or allergic diseases, as well as conditions like transplant rejection. The efficacy of this JAK inhibitor has been demonstrated in animal model tests.
Career Highlights
Liang Fang is currently employed at Zhuhai United Laboratories Co., Ltd., where he continues to advance his research in pharmaceutical innovations. His work has positioned him as a key figure in the development of effective treatments for complex diseases.
Collaborations
Liang collaborates with talented coworkers, including Liwei Mu and Shuai Wang, who contribute to his research efforts and innovations.
Conclusion
Liang Fang's contributions to the field of JAK inhibitors represent a significant advancement in pharmaceutical research. His innovative patents and ongoing work at Zhuhai United Laboratories Co., Ltd. highlight his commitment to improving treatment options for patients with JAK-related diseases.